Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo Controlled, Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Repeat Dose of Inhaled ETD001 in People With Cystic Fibrosis

NCT06478706 is registered in ClinicalTrials.gov with Enterprise Therapeutics Ltd as lead sponsor.

NCT NCT06478706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06478706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo Controlled, Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Repeat Dose of Inhaled ETD001 in People With Cystic Fibrosis
Lead sponsor
Enterprise Therapeutics Ltd
Phase
Phase 2
Overall status
Completed
Start date
June 26, 2024
Completion date
November 14, 2025
Enrollment
57 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis